Paliperidone: Antipsychotic agent treatment of bipolar disorder dual dopamine D2/5-HT2A receptor antagonist

Drugs of the Future

Volumn 31, Issue 7, 2006, Pages 579-584

  Revill, P ^a   Serradell, N ^a   Bolos J ^a  

^a PROUS SCIENCE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE 2 RECEPTOR BLOCKING AGENT; DRUG METABOLITE; NEUROLEPTIC AGENT; OLANZAPINE; PALIPERIDONE; PALIPERIDONE PALMITATE; PALMITIC ACID; PLACEBO; R 084852; R 093725; R 125239; RISPERIDONE; SEROTONIN 2A ANTAGONIST; TRIMETHOPRIM; UNCLASSIFIED DRUG;

ANTISOCIAL BEHAVIOR; BIPOLAR DISORDER; CLINICAL TRIAL; DIZZINESS; DRUG ANTAGONISM; DRUG DOSE REGIMEN; DRUG FORMULATION; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG WITHDRAWAL; EXTRAPYRAMIDAL SYMPTOM; HEADACHE; HUMAN; HYPERKINESIA; MUSCLE HYPERTONIA; REVIEW; SCHIZOPHRENIA; SIDE EFFECT; TREMOR; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN; XEROSTOMIA;

EID: 33750116953     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2006.031.07.1008562     Document Type: Review

References (42)

1. Janssen, C.G.M., Knaeps, A.G., Kennis, L.E.J., Vandenberk, J. (Janssen Pharmaceutica NV). Novel 3-piperidinyl-1,2-benzisoxazoles. EP 0368388, JP 1990191276, US 5158952.
2. Reddy, B.R., Sudhakar, S., Chakka, R., Reddy, T.R., Kumar, K.V.K. (Dr. Reddy's Laboratories, Ltd.; Dr. Reddy's Laboratories, Inc.). Process for the preparation of pure 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl] ethyl]6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one. US 2006004199.
3. Prous Science Drug R&D Backgrounders: Schizophrenia - online publication. Updated June 26, 2006.
4. Marek, G., Merchant, K. Developing therapeutics for schizophrenia and other psychotic disorders. NeuroRx 2005, 2(4): 579-89.
5. Sawa, A., Snyder, S.H. Schizophrenia: Diverse approaches to a complex disease. Science 2002, 296(5568): 692-5.
6. Rowley, M., Bristow, L.J., Hutson, P.H. Current and novel approaches to the drug treatment of schizophrenia. J Med Chem 2001, 44(4): 477-501.
7. Mueser, K.T., McGurk, S.R. Schizophrenia. Lancet 2004, 363(9426): 2063-72.
8. Davis, J.M., Chen, N., Glick, I.D. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 2003, 60(6): 553-64.
9. Vermeir, M., Boom, S., Naessens, I., Talluri, K., Eerdekens, M. Absorption, metabolism and excretion of a single oral dose of 14C-paliperidone 1 mg in healthy subjects. 18th Congr Eur Coll Neuropsychopharmacol (ECNP) (Oct 22-26, Amsterdam) 2005, Abst P.8.097.
10. Vermeir, M., Boom, S., Naessens, I., Talluri, K., Eerdekens, M. Absorption, metabolism and excretion of a single oral dose of 14C-paliperidone 1 mg in five healthy male subjects. Clin Pharmacol Ther 2006, 79(2): Abst PIII-78.
11. Cleton, A., Rossenu, S., Vermeulen, A. et al. A pharmacokinetic model to document the interconversion between paliperidone's enantiomers. Clin Pharmacol Ther 2006, 79(2): Abst PII-72.
12. Karlsson, P., Dencker, E., Nyberg, S. et al. Pharmacokinetics and dopamine D2 and serotonin 5-HT2A receptor occupancy of paliperidone in healthy subjects. 18th Congr Eur Coll Neuropsychopharmacol (ECNP) (Oct 22-26, Amsterdam) 2005, Abst P.1.053.
13. Karlsson, P., Dencker, E., Nyberg, S. et al. Pharmacokinetics and dopamine D2 and serotonin 5-HT2A receptor occupancy of paliperidone in healthy subjects: Two open-label, single-dose studies. Clin Pharmacol Ther 2006, 79(2): Abst PIII-57.
14. Karlsson, P., Dencker, E., Nyberg, S. et al. Pharmacokinetics and dopamine D2 and serotonin 5-HT2A receptor occupancy of paliperidone in healthy subjects. Schizophr Res 2006, 81(Suppl. 1): Abst 125.
15. Chew, M.L., Mulsant, B., Kirshner, M.A., Lehman, M.E., Greenspan, A., Pollock, B.G. Differential anticholinergic activity of 41 psychotropic medications. 61st Annu Meet Soc Biol Psychiatry (SOBP) (May 18-20, Toronto) 2006, Abst 408.
16. Tzimos, A., Kramer, M., Ford, L., Gassmann-Mayer, C., Lim, P., Eerdekens, M. A 6-week placebo-controlled study on the safety and tolerability of flexible doses of oral paliperidone extended-release tablets in the treatment of schizophrenia in elderly patients. 159th Annu Meet Am Psychiatr Assoc (May 20-26, Toronto) 2006, Abst NR441.
17. Emsley, R., Kramer, M., Nuamah, I., Lane, R., Mayorga, A., Eerdekens, M. Analysis of the efficacy and effect on function of paliperidone extended-release tablets in the treatment of young adults with schizophrenia. 159th Annu Meet Am Psychiatr Assoc (May 20-26, Toronto) 2006 2006, Abst NR345.
18. Davidson, M., Emsley, R., Kramer, M. et al. Efficacy, safety and effect on functioning of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: An international 6-week placebo-controlled study. Schizophr Res 2006, 81(Suppl. 1): Abst 17.
19. Davidson, M., Emsley, R., Kramer, M. et al. Efficacy, safety and effect on functioning of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: An international 6-week placebo-controlled study. 159th Annu Meet Am Psychiatr Assoc (May 20-26, Toronto) 2006, Abst NR338.
20. Kane, J.M., Kramer, M., Ford, L., Gassmann-Mayer, C., Lim, P., Eerdekens, M. Treatment of patients with acute schizophrenia using paliperidone extended-release tablets: A 6-week placebo-controlled study. Neuropsychopharmacology 2005, 30(Suppl. 1): Abst 123.
21. Kane, J.M., Kramer, M., Ford, L., Gassmann-Mayer, C., Lim, P., Eerdekens, M. Patients with acute schizophrenia: Treatment with three fixed dosages of oral paliperidone extended-release tablets in an international 6-week placebo-controlled study. 159th Annu Meet Am Psychiatr Assoc (May 20-26, Toronto) 2006, Abst NR375.
22. Marder, S.R., Kramer, M., Ford, L., Eerdekens, E., Lim, P., Eerdekens, M. Efficacy and tolerability of two fixed dosages of paliperidone extended-release tablets in the treatment of acute schizophrenia: A 6-week placebo-controlled study. Neuropsychopharmacology 2005, 30(Suppl. 1): Abst 144.
23. Marder, S.R., Kramer, M., Ford, L., Eerdekens, E., Lim, P., Eerdekens, M. A 6-week, US-based placebo-controlled study on the efficacy and tolerability of two fixed dosages of oral paliperidone extended-release tablets in the treatment of acute schizophrenia. 159th Annu Meet Am Psychiatr Assoc (May 20-26, Toronto) 2006, Abst NR400.
24. Dirks, B., Turkoz, I., Canuso, C., Youssef, E., Sliwa, J.K., Gharabawi, G. Direct effect of paliperidone extended-release tablets on negative symptoms. 159th Annu Meet Am Psychiatr Assoc (May 20-26, Toronto) 2006, Abst NR342.
25. A study of the long-term safety and tolerability and the long-term effectiveness of extended-release oral paliperidone in patients diagnosed with schizophrenia (NCT 00210769). ClinicalTrials.gov Web Site 2006.
26. Safety study with OROS paliperidone in geriatric subjects with schizophrenia (NCT00085748). ClinicalTrials.gov Web site 2006.
27. Extended release OROS paliperidone in treatment of schizophrenia (double blind, placebo-controlled trial, with olanzapine arm) (NCT00083668). ClinicalTrials.gov Web site 2006.
28. 3 Fixed dosages of extended release OROS paliperidone and olanzapine in the treatment of subjects with schizophrenia (NCT00078039). ClinicalTrials.gov Web site 2006.
29. An exploratory study on the safety and effectiveness of paliperidone in patients with schizophrenia (NCT00257023). ClinicalTrials.gov Web site 2006.
30. Trial evaluating the safety and efficacy of 2 doses of ER OROS paliperidone in acute adult schizophrenics (NCT00077714). ClinicalTrials.gov Web site 2006.
31. Evaluating extended-release (ER) OROS paliperidone versus placebo on sleep in schizophrenia subjects (NCT00105326). ClinicalTrials.gov Web site 2006.
32. Study of extended release OROS® paliperidone in the prevention of recurrence in subjects with schizophrenia (NCT00086320). ClinicalTrials.gov Web site 2006.
33. A study to evaluate the efficacy and safety of adjustable doses of extended-release (ER) paliperidone compared with placebo, in combination with lithium or valprote, to treat manic and mixed episodes in patients with bipolar I disorder (NCT00309686). ClinicalTrials.gov Web site 2006.
34. A study to evaluate the efficacy and safety of three fixed doses of extended-release paliperidone in subjects with bipolar I disorder (NCT00299715). ClinicalTrials.gov Web site 2006.
35. A study to evaluate the efficacy and safety of flexible doses of extended-release (ER) paliperidone compared with flexible doses of quetiapine and placebo in patients with bipolar I disorder (NCT00309699). ClinicalTrials.gov Web site 2006.
36. A safety and tolerability study of paliperidone palmitate injected in the shoulder or the buttock muscle in patients with schizophrenia (NCT00119756). ClinicalTrials.gov Web site 2006.
37. A study to evaluate the effectiveness and safety of 3 doses of paliperidone palmitate in treating subjects with schizophrenia (NCT00210548). ClinicalTrials.gov Web site 2006.
38. A study to compare the effectiveness and safety of flexibly varied doses of paliperidone palmitate and risperidone in treating patients with schizophrenia (NCT00210717). ClinicalTrials.gov Web site 2006.
39. Evaluate the efficacy in the prevention of recurrence of the symptoms of schizophrenia (NCT00111189). ClinicalTrials.gov Web site 2006.
40. Safety and efficacy of an anti-psychotic versus placebo in subjects with schizophrenia (NCT00101634). ClinicalTrials.gov Web site 2006.
41. Safety and efficacy of an anti-psychotic versus placebo in subjects with schizophrenia (NCT00147173). ClinicalTrials.gov Web site 2006.
42. Cleton, A., Cleton, A., Talluri, K. et al. No pharmacokinetic interaction between trimethoprim and paliperidone ER in healthy subjects. Clin Pharmacol Ther 2006, 79(2): Abst PI-58.